Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Palisade Bio (PALI) over the last 14 years, with Q3 2025 value amounting to 58440.0%.

  • Palisade Bio's EBITDA Margin changed N/A to 58440.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 143212.5%, marking a year-over-year change of. This contributed to the annual value of 5228.0% for FY2023, which is N/A changed from last year.
  • As of Q3 2025, Palisade Bio's EBITDA Margin stood at 58440.0%.
  • Palisade Bio's 5-year EBITDA Margin high stood at 231000.0% for Q1 2025, and its period low was 1011.6% during Q1 2023.
  • In the last 3 years, Palisade Bio's EBITDA Margin had a median value of 11600.0% in 2021 and averaged 63904.08%.
  • The largest annual percentage gain for Palisade Bio's EBITDA Margin in the last 5 years was 1259838400bps (2021), contrasted with its biggest fall of 830548500bps (2021).
  • Palisade Bio's EBITDA Margin (Quarter) stood at 11600.0% in 2021, then plummeted by -109bps to 1011.6% in 2023, then surged by 5877bps to 58440.0% in 2025.
  • Its EBITDA Margin stands at 58440.0% for Q3 2025, versus 142150.0% for Q2 2025 and 231000.0% for Q1 2025.